Rimstar 150+75+400+275 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

rimstar 150+75+400+275 mg filmovertrukne tabletter

orifarm a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg

Suxamethonium chloride "Aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

suxamethonium chloride "aguettant" 10 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

laboratoire aguettant - suxamethoniumchlorid (vandfrit) - injektionsvæske, opløsning i fyldt injektionssprøjte - 10 mg/ml

Rifampar 150+75+400+275 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

rifampar 150+75+400+275 mg filmovertrukne tabletter

paranova danmark a/s - ethambutolhydrochlorid, isoniazid, pyrazinamidum, rifampicin - filmovertrukne tabletter - 150+75+400+275 mg

Sorafenib "Mylan" 200 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

sorafenib "mylan" 200 mg filmovertrukne tabletter

mylan ab - sorafenibtosylat - filmovertrukne tabletter - 200 mg

Qinlock Unión Europea - danés - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinale stromale tumorer - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Ozawade Unión Europea - danés - EMA (European Medicines Agency)

ozawade

bioprojet pharma - pitolisant - sleep apnea, obstructive - andre narkotika stoffer - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Sorafenib Accord Unión Europea - danés - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiske midler - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Pyrukynd Unión Europea - danés - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Lapatinib "Newbury" 250 mg filmovertrukne tabletter Dinamarca - danés - Lægemiddelstyrelsen (Danish Medicines Agency)

lapatinib "newbury" 250 mg filmovertrukne tabletter

newbury pharmaceuticals ab - lapatinibditosylatmonohydrat - filmovertrukne tabletter - 250 mg

Halaven Unión Europea - danés - EMA (European Medicines Agency)

halaven

eisai gmbh - eribulin - breast neoplasms; liposarcoma - antineoplastiske midler - halaven monoterapi er indiceret til behandling af patienter med lokalt avanceret eller metastatisk brystkræft, der har udviklet sig efter mindst ét ​​kemoterapeutisk regime for avanceret sygdom (se afsnit 5. tidligere behandling skulle have inkluderet en anthracyclin og en taxan, medmindre patienter ikke var egnede til disse behandlinger. halaven er indiceret til behandling af voksne patienter med inoperabel liposarcoma, der har modtaget forudgående antracyklin, der indeholder terapi (medmindre der er uegnet) for avanceret eller metastatisk sygdom (se afsnit 5.